GAITHERSBURG, Md., Sept. 14, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a virtual presentation as part of Maxim Group’s 2023 Virtual Tech Conference Series, Emerging Growth in AI, scheduled to take place from September 26-27, 2023, and hosted on M-VEST. The presentation will include an overview of the company and its programs with a Q&A for investors in virtual attendance to follow.
Presentation Name: BullFrog AI Company Overview
Presenter: Vin Singh, Founder and CEO, BullFrog AI
Date/Time: September 26, 2023 10:30-11:00 a.m. EDT
The two-day event is limited to members of M-VEST. Listeners can sign up here
About BullFrog AI
BullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological clinical and real-world data spanning from early discovery to late-stage clinical trials. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.
For more information visit BullFrog AI at:
Website: https://bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors
Dave Gentry
RedChip Companies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
800-733-2447
Media
Tiberend Strategic Advisors, Inc.
Eric Reiss
This email address is being protected from spambots. You need JavaScript enabled to view it.
802-249-1136
Dave Schemelia
This email address is being protected from spambots. You need JavaScript enabled to view it.
609-468-9325
Last Trade: | US$2.09 |
Daily Change: | -0.02 -0.95 |
Daily Volume: | 123,623 |
Market Cap: | US$18.200M |
October 22, 2024 October 21, 2024 October 09, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB